Consequently, the FDA successively approved Dato-DXd in 2025 for the treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor2 (HER2)-negative breast cancer and locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.